Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer

Drug Development and Industrial Pharmacy

Volumn 36, Issue 10, 2010, Pages 1225-1234

  Gao, Yan ^a   Li, Zhonggang ^a   Sun, Min ^a   Li, Houli ^b   Guo, Chenyu ^a   Cui, Jing ^c   Li, Aiguo ^a   Cao, Fengliang ^a   Xi, Yanwei ^a   Lou, Hongxiang ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Curcumin; High pressure homogenization; Nanosuspensions; Pharmacokinetics; Tissue distribution

Indexed keywords

CURCUMIN; TOCOFERSOLAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MOUSE; NONHUMAN; RABBIT; TISSUE DISTRIBUTION; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; INFUSIONS, INTRAVENOUS; MICE; NANOPARTICLES; NANOSPHERES; PARTICLE SIZE; PHYSICOCHEMICAL PHENOMENA; POLYETHYLENE GLYCOLS; POWDERS; RABBITS; SOLUBILITY; SUSPENSIONS; TISSUE DISTRIBUTION; VITAMIN E;

EID: 77956398535     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639041003695139     Document Type: Article

References (48)

1. Tong YQ, Wang Q, Hou HM. (2008). Protection by Chinese herbs against doxorubicin-induced focal and segmental glomerulosclerosis in rats. Drug Dev Ind Pharm, 34:663-7.
2. Xu PS, Van Kirk EA, Li SY, Murdoch WJ, Ren J, Hussain MD, et al. (2006). Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy. Colloids Surf B Biointerfaces, 48:50-7.
3. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. (1999). The safety of newly approved medicines: Do recent market removals mean there is a problem? J Am Med Assoc, 281:1728-34.
4. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. (2005). Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappa B and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem, 280:6301-8.
5. Aggarwal BB, Surh YJ, Shishodia S. (2007). The molecular targets and therapeutic uses of curcumin in health and disease. Advances in experimental medicine and biology. New York: Springer.
6. Aggarwal BB, Harikumar KB. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol, 41:40-59.
7. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007). Bioavailability of curcumin: Problems and promises. Mol Pharm, 4:807-18.
8. Tonnesen HH, Masson M, Loftsson T. (2002). Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: Solubility, chemical and photochemical stability. Int J Pharm, 244:127-35.
9. Sigfridsson K, Lundqvist AJ, Strimfors M. (2009). Particle size reduction for improvement of oral absorption of the poorly solubledrug UG558 in rats during early development. Dev Ind Pharm, 35:1479-86.
10. Lao CD, Ruffin MTT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. (2006). Dose escalation of a curcuminoid formulation. BMC Complement Altern Med, 6:10-3.
11. Briones E, Colino CI, Lanao JM. (2008). Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Release, 125:210-27.
12. Keck CM, Müller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm, 62:3-16.
13. Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R. (2008). Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm, 34:1209-18.
14. Li X, Gu L, Xu Y, Wang Y. (2009). Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm, 35:827-33.
15. Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3-19.
16. Ganta S, Paxton JW, Baguley BC, Garg S. (2009). Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm, 367:179-86.
17. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, et al. (2000). Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother, 45:77-83.
18. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. (2008). Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm, 364:64-75.
19. Gao L, Zhang DR, Chen MH, Duan CX, Dai WT, Jia LJ, et al. (2008a). Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm, 355:321-7.
20. Gao Y, Li LB, Zhai GX. (2008b). Preparation and characterization of pluronic/TPGS mixed micelles for solubilization camptothecin. Colloids Surf B Biointerfaces, 64:194-9.
21. Mu L, Seow PH. (2006). Application of TPGS in polymeric nanoparticulate drug delivery system. Colloids Surf B Biointerfaces, 47:90-7.
22. Feng SS, Mu L, Win KY, Huang GF. (2004). Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem, 11:413-24.
23. Traber MG, Schiano TD, Steephen AC, Kayden HJ, Shike M. (1994). Efficacy of water-soluble vitamin E in the treatment of vitamin E malabsorption in short-bowel syndrome. Am J Clin Nutr, 59:1270-74.
24. Win KY, Feng SS. (2006). In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d,l-lactic-/i co/-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials, 27:2285-91.
25. Bogman K, Erne-Brand F, Alsenz J, Drewe J. (2003). The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci, 92:1250-61.
26. Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J, et al. (2005). P-glycoprotein and surfactants: Effect on intestinal talinolol absorption. Clin Pharm Ther, 77:24-32.
27. Dintaman JM, Silverman JA. (1999). Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res, 16:1550-6.
28. Rege BD, Kao JPY, Polli JE. (2002). Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci, 16:237-46.
29. Zhang JQ, Liu J, Li YL, Jasti BR. (2007). Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv, 15:381-7.
30. Zhang DR, Tan TW, Gao L, Zhao W, Wang P. (2007). Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm, 33:569-75.
31. Ma ZS, Shayeganpour A, Brocks DR, Lavasanifar A, Samuel J. (2007). High-performance liquid chromatography analysis of curcumin in rat plasma: Application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr, 21:546-52.
32. Gao L, Zhang DR, Chen MH, Zheng TT, Wang SM. (2007). Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm, 33:1332-9.
33. Mauludin R, Müller RH, Keck CM. (2009). Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm Biopharm, 36:502-10.
34. Wei CM, Zhang R, Wang BJ, Yuan GY, Guo RC. (2008). Determination and pharmacokinetic study of norcantharidin in human serum by HPLC-MS/MS method. Biomed Chromatogr, 22:44-9.
35. Voorhees PW. (1985). The theory of Ostwald ripening. J Stat Phys, 38:232-52.
36. Jacobs C, Kayser O, Müller RH. (2000). Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm, 196:161-4.
37. Hemar Y, Horne DS. (1999). A diffusing wave spectroscopy study of the kinetics of Ostwald ripening in protein-stabilised oil/water emulsions. Colloids Surf B Biointerfaces, 12:239-46.
38. Mishra PR, Al Shaal L, Müller RH, Keck CM. (2009). Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm, 371:182-9.
39. Baert L, Vant Klooster G, Dries W, Francois M, Wouters A, Basstanie E, et al. (2009). Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm, 72:502-8.
40. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Grozdanis MT, Lenhardt T, et al. (2007). Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev, 59:419-26.
41. Pak Y, Patek R, Mayersohn M. (2003). Sensitive and rapid isocratic liquid chromatography method for the quantitation of curcumin in plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 796:339-46.
42. Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, et al. (2005). Nanosuspension formulations for low-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm, 31:319-29.
43. Yao J, Zhou JP, Ping QN, Lu Y, Chen L. (2008). Distribution of nobiletin chitosan-based microemulsions in brain following i.v. injection in mice. Int J Pharm, 352:256-62.
44. Stolnik S, Illum L, Davis SS. (1995). Long circulating microparticulate drug carriers. Adv Drug Deliv Rev, 16:195-214.
45. Ben Zirar S, Astier A, Muchow M, Gibaud S. (2008). Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm, 70:649-56.
46. Gururajan M, Dasu T, Shahidain S, Jennings CD, Robertson DA, Rangnekar VM, et al. (2007). Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol, 178:111-21.
47. Moghaddam SJ, Barta P, Mirabolfathinejad SG, Ammar- Aouchiche Z, Torres Garza N, Vo TT, et al. (2009). Curcumin inhibits COPD-Like airway inflammation and lung cancer progression in mice. Carcinogenesis, 30:1949-56.
48. Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Suyasunanont D, Klaikeaw N. (2009). Curcumin decreased oxidative stress, inhibited NF-kappaB activation, and improved liver pathology in ethanol-induced liver injury in rats. J Biomed Biotechnol, 2009:981963.